US life expectancy hit an all-time high in 2024, CDC says

U.S. life expectancy rose to 79 years in 2024 — the highest on record — as total deaths declined to about 3.07 million, roughly 18,000 fewer than the prior year. Declines were broad-based: heart disease mortality fell about 3% for the second consecutive year, unintentional-injury deaths (including overdoses) dropped more than 14%, and COVID-19 fell out of the top 10 causes; preliminary 2025 counts (~3.05 million) suggest further improvement. The turnaround reflects a sustained recovery from the pandemic and easing of the overdose crisis, with potential implications for healthcare demand, longevity assumptions and labor-force/demographic projections relevant to long-duration investors and pension models.

Analysis

Market structure: Rising U.S. life expectancy to 79 (2024) and preliminary 2025 improvement favors companies exposed to chronic-disease management (pharma makers of GLP‑1s like LLY, NVO), diagnostics/ambulatory care, and reinsurers that profit from lower claim incidence (RGA). Conversely, acute-care hospital throughput (HCA) and short-term inpatient services face pricing pressure if fewer acute events persist; life insurers (PRU, MET, LNC) face rising long-duration liabilities and potential reserve adjustments. The shift reallocates healthcare demand toward pharmaceuticals, outpatient services, and long-term care financing, pushing margin expansion for scalable drug franchises and compressing episodic hospital revenue over 1–5 years.

Risk assessment: Tail risks include a new pandemic wave or fentanyl-driven overdose surge that reverses mortality gains (low-probability, high-impact) and regulatory/price-containment measures on GLP‑1s in the U.S./EU within 6–18 months. Near-term (days–weeks) market moves will be sentiment-driven; medium-term (3–12 months) earnings/reserve revisions matter for insurers; long-term (2–7 years) pension/annuity liabilities and longevity hedging reshape bond demand. Hidden dependencies: adoption rates of weight‑loss drugs, reimbursement changes, and reinsurance pricing cycles—monitor FDA/CDC announcements and CMS/Medicare policy steps over 30–90 days.

Trade implications: Favor concentrated exposure to LLY and NVO via 6–12 month call spreads (capped risk) to capture continued GLP‑1 adoption; overweight RGA (reinsurance) and UNH (integrated care) for durable margin improvement, size 1–3% each. Short selective hospital operators (HCA) and selectively hedge life insurers (PRU, MET) via 3–9 month put spreads or buy‑write collars to protect against reserve-driven drawdowns; add 1–2% allocation to long-duration Treasuries (TLT) as a structural hedge against longer-duration liabilities.

Contrarian angles: The market may underprice the multi-year liability impact on insurers—mortality improvement is gradual but persistent, likely increasing annuity demand and driving a curve steepening into long-duration bonds over 2–5 years. Conversely, consensus may overrate GLP‑1 upside without accounting for pricing caps or supply constraints; that argues for option-defined exposures, not naked longs. Historical parallel: post‑HIV and cardiovascular therapy advances reallocated spend away from acute care to chronic management over a decade, a pattern that could repeat here.

Key Decisions for Investors

• Establish a 2–3% long position in Eli Lilly (LLY) and Novo Nordisk (NVO) combined (split 50/50) via 6–12 month call spreads (e.g., buy ATM, sell OTM ~20% strike) to capture GLP‑1 adoption while capping downside; reassess after 6‑month sales prints and any CMS pricing actions.
• Initiate a 1–2% long position in Reinsurance Group of America (RGA) to play falling life claims and potential reserve tailwind, using stock or 9–12 month bull call spreads; trim if mortality indicators reverse >5% quarter-over-quarter.
• Enter a 1–2% short position in hospital operator HCA (HCA) as a pair with long UNH (UNH) (long 1%, short 1%) over a 6–18 month horizon to express outpatient shift; use short equity or buy 3–9 month put spreads on HCA funded by calls on UNH.
• Hedge life-insurer exposure: buy 3–6 month put spreads on PRU or MET sized to cover 1–2% portfolio exposure (e.g., buy 8–12% OTM puts, sell deeper OTM puts) ahead of next earnings/actuarial reserve updates; monitor regulatory/policy announcements over next 30–60 days.
• Allocate 1–2% to long-duration Treasuries (TLT) or buy 3–7 year Treasury futures as a structural hedge against rising pension/annuity duration risks; increase if new CMS/SEC guidance materially raises projected longevity assumptions.